196 results on '"Nichols, Erin"'
Search Results
2. Community-Based Testing Sites for SARS-CoV-2 — United States, March 2020–November 2021
3. Household Transmission of Ebola Virus : Risks and Preventive Factors, Freetown, Sierra Leone, 2015
4. Peeling Back the Layers: Prototyping Systemic Transformation through the Circular Food Innovation Lab
5. "It's like Lifting the Power": Powerlifting, Digital Gendered Subjectivities, and the Politics of Multiplicity.
6. Asymmetric Hydrative Aldol Reaction (HAR) via Vinyl‐Gold Promoted Intermolecular Ynamide Addition to Aldehydes
7. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
8. Can verbal autopsies be used on a national scale? Key findings and lessons from South Africa's national cause-of-death validation study.
9. Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
10. Civil registration and vital statistics: progress in the data revolution for counting and accountability
11. Mortality surveillance during the COVID-19 pandemic
12. Diffractive Respondings and Cutting Together-Apart: Toward More-Than-Human Academic Community
13. The Special Issue as Diffractive Process: A Collaborative Dialogue
14. Feminist New Materialist Entanglements With “Kinetic Excess” in Women’s Muay Thai Boxing: Moving With Embodied Discomfort as a Post-Qualitative Coach-Researcher
15. Can verbal autopsies be used on a national scale? Key findings and lessons from the South Africa National Cause-of-Death Validation Study.
16. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
17. Mixed-methods analysis of select issues reported in the 2016 World Health Organization verbal autopsy questionnaire
18. Evaluation of approaches to strengthen civil registration and vital statistics systems: A systematic review and synthesis of policies in 25 countries
19. Improving mortality data in Jordan: a 10 year review/Ameliorer les donnees de mortalite en Jordanie: analyse decennale/Mejora de los datos sobre mortalidad en Jordania: analisis de los ultimos 10 anos
20. Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells
21. Estimating causes of death where there is no medical certification: evolution and state of the art of verbal autopsy
22. “It’s like Lifting the Power”: Powerlifting, Digital Gendered Subjectivities, and the Politics of Multiplicity
23. Risk factors for Ebola virus disease among household care providers, Sierra Leone, 2015.
24. The WHO 2016 verbal autopsy instrument: An international standard suitable for automated analysis by InterVA, InSilicoVA, and Tariff 2.0
25. Psychological distress in Australian psychology undergraduates: Exploring the role of self-care, dispositional mindfulness, and autonomous functioning
26. “I Would Report It Even If They Have Not Committed Anything”: Social Service Students’ Attitudes Toward Minor-Attracted People
27. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab
28. Sisterhood and affective politics: The CaiRollers mobilising change through roller derby in Egypt
29. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
30. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
31. "I Would Report It Even If They Have Not Committed Anything": Social Service Students' Attitudes Toward Minor-Attracted People.
32. Additional file 5: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1â 3 inhibitor, cediranib, in recurrent womenâ s cancers with biomarker analyses
33. Additional file 2: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
34. Additional file 4: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
35. Additional file 1: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
36. Additional file 3: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1â 3 inhibitor, cediranib, in recurrent womenâ s cancers with biomarker analyses
37. Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.
38. Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.
39. National health information systems for achieving the Sustainable Development Goals
40. Additional file 2: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
41. A systematic review of vital events tracking by community health agents
42. The Resource Curse: A Look into the Implications of an Abundance of Natural Resources in the Democratic Republic of Congo
43. Process Improvement of Thermoregulation for Elbw Neonates During Critical Care Transport*
44. Integrating community-based verbal autopsy into civil registration and vital statistics (CRVS) : system-level considerations
45. Interagency technical consultation on improving mortality reporting in Sierra Leone: meeting report
46. Micrometastatic Dormancy in Uveal Melanoma: A Comprehensive Review of the Evidence, Mechanisms, and Implications for Future Adjuvant Therapies
47. Integrating community-based verbal autopsy into civil registration and vital statistics (CRVS): system-level considerations
48. Disparities in Uveal Melanoma: Patient Characteristics
49. Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma
50. Socioeconomic Disparities in Cataract Prevalence, Characteristics, and Management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.